Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation

Thewis, André; Bucher, Christoph; Rovó, Alicia; Stüssi, Georg; Stangel, Martin; Paulussen, Michael; Halter, Jörg; Meyer-Monard, Sandrine; Heim, Dominik; Tsakiris, Dimitrios Α.; Biedermann, Barbara C.; Passweg, Jakob; Gratwohl, Aloïs

doi:10.1182/blood-2006-10-054080

Cited by 214 publications

(205 citation statements)

References 39 publications

Supporting

Mentioning

191

Contrasting

Unclassified

Order By: Relevance

“…8,9 In our study, diabetes, hypothyroidism and hyperlipidemia were observed in 4 (11%), 9 (26%) and 10 (30%) patients, respectively. One patient had myocardial infarction.…”

supporting

confidence: 49%

Long-term outcomes in adult patients below the age of 55 years with acute lymphoblastic leukemia treated with chemotherapy or allogeneic BM transplant in first CR

Kohli

Brandwein

et al. 2009

Bone Marrow Transplant

View full text Add to dashboard Cite

“…8,9 In our study, diabetes, hypothyroidism and hyperlipidemia were observed in 4 (11%), 9 (26%) and 10 (30%) patients, respectively. One patient had myocardial infarction.…”

supporting

confidence: 49%

Long-term outcomes in adult patients below the age of 55 years with acute lymphoblastic leukemia treated with chemotherapy or allogeneic BM transplant in first CR

Kohli

Brandwein

et al. 2009

Bone Marrow Transplant

View full text Add to dashboard Cite

“…A recent retrospective single-center cohort study showed that long-term survivors post allo-HSCT are at risk for cardiovascular disease, as compared with patients treated with autologous transplantation. 29 Baker et al 30 have found that HSCT survivors have a higher risk of diabetes and hypertension, which potentially lead to higher cardiovascular events. In our univariate and multivariate analyses age group, conditioning therapy (TBI-based vs non-TBIbased), transplant type (related vs unrelated), primary diagnosis or chronic GVHD did not seem as risk factors for CAD (Table 3).…”

Section: Discussionmentioning

confidence: 99%

Long-term outcome after allo-SCT: close follow-up on a large cohort treated with myeloablative regimens

Abou-Mourad

Lau

Barnett

et al. 2009

Bone Marrow Transplant

View full text Add to dashboard Cite

We analyzed the late outcomes of 429 long-term survivors post allogeneic hematopoietic SCT (allo-HSCT) who received transplant in our center between 1981 and 2002, and were free of their primary disease for X2 years after allo-HSCT. Late recurrent primary malignancy was found in 58 (13.5%) patients and was the primary cause of late death. A total of 37 (8.6%) patients died of nonrelapse causes at a median of 5.5 years (range, 2-15.6 years) post allo-HSCT. The major non-relapse causes of death were chronic GVHD (cGVHD), secondary malignancy and infection. The probabilities of OS and EFS were 85% (95% cumulative incidence (CI) (81-89%)) and 79% (95% CI (74-83%)) at 10 years, respectively. Long-term allo-HSCT survivors were evaluated for late complications (median follow-up, 8.6 years (range, 2.3-22.8 years)). cGVHD was diagnosed in 196 (53.1%) survivors. The endocrine and metabolic complications were hypogonadism in 134 (36.3%) patients, osteopenia/ osteoporosis in 90 (24.4%), dyslipidemia in 33 (8.9%), hypothyroidism in 28 (7.6%) and diabetes in 28 (7.6%). Hypertension was diagnosed in 79 (21.4%), renal impairment in 70 (19.0%), depression in 40 (10.8%) and sexual dysfunction in 33 (8.9%) survivors. We conclude that in patients who receive allo-HSCT as treatment for hematological malignancy and who are free of their original disease 2 years post transplant, mortality is low and the probability of durable remission is high. Lifelong surveillance is recommended.

show abstract

“…However, diabetes was often associated with other cardiovascular risk factors, such as arterial hypertension, dyslipidemia and unhealthy heart lifestyle. [67][68][69] In summary, hyperglycemia after allo-HSCT is common and is associated with an increase in morbidity and NRM.…”

Section: Ptdm and Clinical Outcomesmentioning

confidence: 99%

How do I manage hyperglycemia/post-transplant diabetes mellitus after allogeneic HSCT

Fuji

Rovó

Ohashi

et al. 2016

Bone Marrow Transplant

View full text Add to dashboard Cite

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients frequently develop glucose intolerance and post-transplant diabetes mellitus (PTDM). The clinical importance of PTDM and its detrimental impact on HSCT outcomes are underrecognized. After allo-HSCT, various mechanisms can contribute to the development of PTDM. Here we review information about hyperglycemia and PTDM after allo-HSCT as well as PTDM after solid organ transplantation and describe ways to manage hyperglycemia/PTDM after allogeneic HSCT. Taking into consideration a lack of well-established evidence in the field of allo-HSCT, more studies should be conducted in the future, which will require closer multidisciplinary collaboration between hematologists, endocrinologists and nutritionists.

show abstract

Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation

Cited by 214 publications

References 39 publications

Long-term outcomes in adult patients below the age of 55 years with acute lymphoblastic leukemia treated with chemotherapy or allogeneic BM transplant in first CR

Long-term outcomes in adult patients below the age of 55 years with acute lymphoblastic leukemia treated with chemotherapy or allogeneic BM transplant in first CR

Long-term outcome after allo-SCT: close follow-up on a large cohort treated with myeloablative regimens

How do I manage hyperglycemia/post-transplant diabetes mellitus after allogeneic HSCT

Contact Info

Product

Resources

About